FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3203843865> ?p ?o ?g. }

• W3203843865 endingPage "2963" @default.
• W3203843865 startingPage "2955" @default.
• W3203843865 abstract "Treatment of Asherman syndrome (AS) presents a significant clinical challenge. Based on our in vitro data showing that PRP could activate endometrial cell proliferation and migration, we hypothesized that intrauterine infusion of autologous platelet-rich plasma (PRP) may improve endometrial regeneration and fertility outcomes in patients with moderate-severe AS.Subjects with moderate-severe AS were randomized to PRP or saline control administered following hysteroscopic adhesiolysis. Due to relative inability to randomize patients to the control group, after initial randomization of 10 subjects (6 in PRP and 4 in control groups), the remainder were prospectively enrolled in PRP group (n = 9), with 11 historic controls added to control group, for a total of 30 subjects (PRP n = 15; saline control n = 15). Right after hysteroscopy, 0.5-1 mL of PRP or saline was infused into the uterus via a Wallace catheter, followed by estrogen therapy. The primary outcomes were changes in endometrial thickness (EMT, checked in 3 weeks) and in menstrual flow; secondary outcomes were pregnancy and live birth rates. EMT and menstrual bleeding pattern were assessed before and after the intervention. Pregnancy was assessed over a 6-month period.There were no statistically significant differences in age, gravidity/parity, cause of AS, preoperative menses assessment, AS hysteroscopy score, and intrauterine balloon placement between the groups. There was no statistically significant difference (p = 0.79) in EMT pre-PRP infusion for control (5.7 mm, 4.0-6.0) and study arm (5.3 mm, 4.9-6.0). There was no statistically significant change (p = 0.78) in EMT after PRP infusion (1.4 mm, - 0.5-2.4) vs saline (1.0 mm, 0.0-2.5). Patients tolerated the procedure well, with no adverse effects. There was no difference in the predicted likelihood of pregnancy (p = 0.45) between the control (0.67, 0.41-0.85) and study arm (0.53, 0.29-0.76).PRP was well accepted and tolerated in AS patients. However, we did not observe any significant EMT increase or improved pregnancy rates after adding PRP infusion, compared to standard treatment only. The use of intrauterine PRP infusion may be a feasible option, and its potential use must be tested on a larger sample size of AS patients." @default.
• W3203843865 created "2021-10-11" @default.
• W3203843865 creator A5008600549 @default.
• W3203843865 creator A5008732135 @default.
• W3203843865 creator A5025275560 @default.
• W3203843865 creator A5064444996 @default.
• W3203843865 creator A5074289517 @default.
• W3203843865 creator A5079037868 @default.
• W3203843865 creator A5085735619 @default.
• W3203843865 date "2021-10-06" @default.
• W3203843865 modified "2023-10-17" @default.
• W3203843865 title "Autologous platelet-rich plasma treatment for moderate-severe Asherman syndrome: the first experience" @default.
• W3203843865 cites W1796876649 @default.
• W3203843865 cites W1964104983 @default.
• W3203843865 cites W1983115419 @default.
• W3203843865 cites W1983156153 @default.
• W3203843865 cites W1983185115 @default.
• W3203843865 cites W1992167600 @default.
• W3203843865 cites W1992962817 @default.
• W3203843865 cites W2000141319 @default.
• W3203843865 cites W2002743674 @default.
• W3203843865 cites W2010608415 @default.
• W3203843865 cites W2010899501 @default.
• W3203843865 cites W2014667076 @default.
• W3203843865 cites W2042374015 @default.
• W3203843865 cites W2071508505 @default.
• W3203843865 cites W2079143326 @default.
• W3203843865 cites W2080485793 @default.
• W3203843865 cites W2080519990 @default.
• W3203843865 cites W2080900526 @default.
• W3203843865 cites W2082494913 @default.
• W3203843865 cites W2094345579 @default.
• W3203843865 cites W2099284074 @default.
• W3203843865 cites W2130146890 @default.
• W3203843865 cites W2308714122 @default.
• W3203843865 cites W2327139271 @default.
• W3203843865 cites W2409369797 @default.
• W3203843865 cites W2604137284 @default.
• W3203843865 cites W2604435318 @default.
• W3203843865 cites W2609586484 @default.
• W3203843865 cites W2621178796 @default.
• W3203843865 cites W2729567989 @default.
• W3203843865 cites W2741269027 @default.
• W3203843865 cites W2786915841 @default.
• W3203843865 cites W2788601288 @default.
• W3203843865 cites W2790496460 @default.
• W3203843865 cites W2901529367 @default.
• W3203843865 cites W2903482846 @default.
• W3203843865 cites W2906764558 @default.
• W3203843865 cites W2966040156 @default.
• W3203843865 cites W3006603875 @default.
• W3203843865 cites W3008683898 @default.
• W3203843865 cites W3026419623 @default.
• W3203843865 cites W339589678 @default.
• W3203843865 doi "https://doi.org/10.1007/s10815-021-02328-5" @default.
• W3203843865 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8609080" @default.
• W3203843865 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34613578" @default.
• W3203843865 hasPublicationYear "2021" @default.
• W3203843865 type Work @default.
• W3203843865 sameAs 3203843865 @default.
• W3203843865 citedByCount "7" @default.
• W3203843865 countsByYear W32038438652022 @default.
• W3203843865 countsByYear W32038438652023 @default.
• W3203843865 crossrefType "journal-article" @default.
• W3203843865 hasAuthorship W3203843865A5008600549 @default.
• W3203843865 hasAuthorship W3203843865A5008732135 @default.
• W3203843865 hasAuthorship W3203843865A5025275560 @default.
• W3203843865 hasAuthorship W3203843865A5064444996 @default.
• W3203843865 hasAuthorship W3203843865A5074289517 @default.
• W3203843865 hasAuthorship W3203843865A5079037868 @default.
• W3203843865 hasAuthorship W3203843865A5085735619 @default.
• W3203843865 hasBestOaLocation W32038438652 @default.
• W3203843865 hasConcept C126322002 @default.
• W3203843865 hasConcept C131872663 @default.
• W3203843865 hasConcept C160099875 @default.
• W3203843865 hasConcept C168563851 @default.
• W3203843865 hasConcept C204243189 @default.
• W3203843865 hasConcept C2775963564 @default.
• W3203843865 hasConcept C2776537878 @default.
• W3203843865 hasConcept C2777397205 @default.
• W3203843865 hasConcept C2778279030 @default.
• W3203843865 hasConcept C2779234561 @default.
• W3203843865 hasConcept C2779742232 @default.
• W3203843865 hasConcept C2780076745 @default.
• W3203843865 hasConcept C29456083 @default.
• W3203843865 hasConcept C54355233 @default.
• W3203843865 hasConcept C71924100 @default.
• W3203843865 hasConcept C86803240 @default.
• W3203843865 hasConcept C89560881 @default.
• W3203843865 hasConceptScore W3203843865C126322002 @default.
• W3203843865 hasConceptScore W3203843865C131872663 @default.
• W3203843865 hasConceptScore W3203843865C160099875 @default.
• W3203843865 hasConceptScore W3203843865C168563851 @default.
• W3203843865 hasConceptScore W3203843865C204243189 @default.
• W3203843865 hasConceptScore W3203843865C2775963564 @default.
• W3203843865 hasConceptScore W3203843865C2776537878 @default.
• W3203843865 hasConceptScore W3203843865C2777397205 @default.
• W3203843865 hasConceptScore W3203843865C2778279030 @default.

• next